Assistant Investigator, Patient Oriented Research, The Feinstein Institute for Medical Research
Assitant Professor of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
Phone: (516) 562-4280
Dr. Hirsch’s clinical experience in infectious disease with a professional focus on medication safety and pharmaceutical utilization has led him to focus on prevention and treatment of infectious complications. My career includes board certification in Geriatric medicine as well as Infectious Diseases. During four years of practicing Geriatric medicine, he has been directly confronted by the enhanced vulnerability to infections in elderly debilitated persons. The evolution of infectious pathogens including antimicrobial resistance has been dramatic over two decades of clinical management of infectious diseases.
Dr. Hirsch’s immersion in clinical infectious disease with a leadership role in medication management in the hospital and health system as Chair of Pharmacy & Therapeutics Committee has given him a unique perspective. He has a record of accomplishment and experience in his current position. He has participated in studies evaluating the impact of copper surfaces on the bacterial bio-burden of patient care environments. Dr. Hirsch is fully committed to the goal of enhancing the safety of medical procedures and preventing spread of resistant bacterial pathogens.
Dr. Hirsch’s current research focus is on the role of the gut microbiome in health and disease. His clinical experience with fecal transplantation for recurrent Clostridium difficile infection has inspired additional areas of focus. Current research interests focus on the role of gut microbiome in health and disease. Projects in gut microbiome in patients with recurrent resistant urinary tract infections and a project that evaluates cytokine levels in patients with Non-Alcoholic Steatohepatitis and realtionship with gut microbiome and diet is currently in development. With ID fellows, a project that evaluates HIV patients with well controlled virus but low immune reconsitution is in early stages with plans to follow up published reasearch on gut microbiome correlates as well as a project evaluating impact of extended infusion of the antibiotic Cefoxitin for ESBL producing E coli urinary tract infections.
2014 Reviewer, Health Environments Research & Design Journal
2014 Innovator’s Award; Peggy Lillis Foundation, Fighting C diff through Education and Advocacy
2010 MDx Medical Inc.
2009 Compassionate Doctor certification on Vitals.com
2009 Top Doctor, Castle Connelly